Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level

AIDS

Volumn 18, Issue 1, 2004, Pages 45-49

  Viard, Jean Paul ^a   Burgard, Marianne ^a   Hubert, Jean Baptiste ^b   Aaron, Laurent ^a   Rabian, Cécile ^a   Pertuiset, Nathalie ^a   Lourenço, Maria ^a   Rothschild, Chantal ^a   Rouzioux, Christine ^a,c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

CD4 cells; Highly active antiretroviral therapy; HIV 1 DNA; HIV 1 infection; Plasma HIV 1 RNA

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MITOCHONDRIAL DNA DISORDER; MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LONG-TERM CARE; MALE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 1642506123     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200401020-00005     Document Type: Article

References (16)

1. Blankson JN, Persaud D, Siliciano R. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002, 53:557-593.
2. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622.
3. Kaufmann R, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14:959-969.
4. Burgard M, Chaix ML, Ngo N, Leruez M, Rouzioux C, and the French Perinatal HIV Infection Study Group. Real-time HIV-1 PCR for the diagnosis of infection in newborn of African mothers. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 243].
5. Diggle PJ, Liang KY, Zeger SL. Fitting smooth curves to longitudinal data. In Analysis of Longitudinal Data. Edited by Atkinson AC, Copas JB, Pierce DA, Schervish MJ, Titterington DM. Oxford: Oxford University Press; 1994:41-47.
6. Izopet J, Salama G, Pasquier C, Sandres K, Marchou B, Massip P, et al. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:478-483.
7. Burgard M, Izopet J, Dumon B, Tamalet C, Descamps D, Ruffault A, et al. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. AIDS Res Hum Retroviruses 2000, 16:1939-1947.
8. Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 2002, 185:1409-1416.
9. Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, et al. Proviral HIV-1 DNA in subjects followed since primary infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001, 15:665-673.
10. Garrigue I, Pellegrin I, Hoen B, Dumon B, Harzic M, Schrive MH, et al. Cell-associated HIV-1 DNA quantitation after HAART-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. AIDS 2000, 14:2851-2856.
11. Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFNγ: results from the Primoferon (ANRS 086) Study. AIDS 2001, 15:1435-1437.
12. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000, 14:2805-2812.
13. Jubault V, Burgard M, Le Corfec E, Costagliola D, Rouzioux C, Viard JP. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. AIDS 1998, 12:2358-2359.
14. Rouzioux C. Early HIV-1 DNA level predicts disease progression and death independently of HIV-RNA level and CD4 count. First International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [abstract A23].
15. Kostrikis LG, Touloumi G, Karanicolas R, Pantazis N, Anastassopoulou C, Karafoulidou A, et al. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in pripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002; 76:10099-10108.
16. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, et al. Increase and plateau of CD4 T-cell counts in the 31/2 years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:168-175.